Neurenati is developing the combination therapy NEU-001 for Hirschsprung disease, as well as diagnostic tools and biomarkers designed to improve the care of patients with Hirschsprung disease, while paving the way for other indications for NEU-001.
NEU-001 combination therapyHirschsprung disease Inflammatory bowel disease |
DISCOVERY
|
IND-ENABLING
|
Phase 1
|
Diagnostic tools for Hirschsprung diseaseNEU-CM1: Colonic manometry pre-surgery |
DISCOVERY
|
Phase 0
Q3-2026
|
Phase 1
|
Hirschsprung disease biomarkersNEU-DO1: Diagnostic NEU-DO2: Disease monitoring |
DISCOVERY
|
CLINICAL VALIDATION
|
|